Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Satellos Bioscience ( (TSE:MSCL) ) is now available.
Satellos Bioscience announced it will present its first-ever Phase 1 safety and pharmacokinetic data for SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. This presentation marks a significant milestone for Satellos, highlighting the potential of SAT-3247 as a novel treatment for Duchenne muscular dystrophy and its continued progress in clinical trials, which may enhance its position in the biotech industry.
More about Satellos Bioscience
Satellos Bioscience Inc. is a public biotechnology company focused on developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The company is advancing its proprietary oral drug, SAT-3247, aimed at regenerating skeletal muscle in conditions such as Duchenne muscular dystrophy, independent of dystrophin and exon mutation status.
YTD Price Performance: -15.53%
Average Trading Volume: 166,300
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $78.85M
Learn more about MSCL stock on TipRanks’ Stock Analysis page.
